Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1997

View Archived Issues

Mylan enters distribution agreement for ranitidine

Repligen identifies angiogenic growth factor inhibitors

Merck KGaA discloses novel ET antagonists

RPR prepares novel transfection agents

Ilex Oncology: Q2 1997 highlights

Statins protect against stroke and CVD

InSite Vision: Q2 1997 highlights

Melarsoprol normalizes cytokine levels in human African trypanosomiasis

Roche seeks U.S. and European approval for Corange takeover

Unigene Laboratories and Parke-Davis to develop oral calcitonin for osteoporosis

Papaverine/phentolamine compared to PGE1 for erectile dysfunction

Advantage-24 safe for evaluation in HIV prevention

Picotamide suppresses ACE inhibitor-induced cough

Review of preclinical and clinical studies with xanomeline

SangStat Medical reports encouraging phase III results with Thymoglobulin

Talsaclidine: favorable preclinical and pharmacokinetic profile

Vivus launches new device for erectile dysfunction in the U.S.

Sepracor reports promising phase II results for norastemizole

Antiherpes activity of naturally occurring flavone alone and in combination with aciclovir

Pharmacopeia receives SBIR grant for development of plasmepsin inhibitors

Jenner licenses emulsion formulation from Walter Reed

D-Pharm reports results from toxicity study for neuroprotective compound

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.